Last updated: May 25, 2026
Bupropion hydrochloride (marketed as “bupropion HBr” in some listings and salts) is a widely sourced small-molecule antidepressant API and intermediate supply chain. Suppliers fall into two buckets: (1) API manufacturers that produce bupropion hydrobromide or convert to the commercial salt form, and (2) contract manufacturers that provide drug product or intermediates under tolling/CMO arrangements. Supply availability is concentrated in large-scale chemical/API houses plus specialty CMOs that support tablets and modified-release formats.
Who supplies bupropion hydrochloride (bupropion HBr) API, and which companies are active?
Core answer: bupropion API supply is dominated by multi-product chemical/API manufacturers and CMOs that support antidepressants and CNS generics. Many brands list multiple manufacturers in DMFs, and multiple API grades are sold into generic and drug product markets.
Which API producers make bupropion hydrobromide or related bupropion salts?
Common practice for bupropion supply is API production at the “bupropion base” stage with subsequent salt formation (including hydrobromide), or direct manufacture of the salt used in a downstream controlled substance of specifications. In regulatory filings, you will see manufacturer names tied to:
- Drug Master Files (DMFs) for bupropion API or intermediates
- API CoA/supplier statements in ANDA/bridging packages
- Commercial packaging site listings in drug product approvals
What CMO and drug product suppliers support bupropion (tablets and extended-release)?
Drug product supply is split between:
- Immediate-release tablet CMOs for bupropion HCl and/or salt-equivalent forms
- Extended-release formulations (including XL-style products) requiring controlled-release matrix processing and tight impurity controls
- Packaging and labeling sites for branded and generic distribution
How to identify the real supplier list (API vs finished dose) from public records?
High-intent supplier lists for bupropion are built by mapping three layers:
- API DMF holders and associated “manufacturer of drug substance” entries
- Drug product “manufactured for” and “distributed by” label statements
- ANDA and supplement filing entities tied to manufacturing sites
This is the only workflow that separates “sales distributors” from the actual production source.
How many bupropion hydrobromide suppliers exist, and how concentrated is the supply?
Core answer: bupropion is not a single-source API. Supply is typically diversified across multiple DMF holders and multiple drug product manufacturing sites. Concentration risk is more acute at the intermediate or salt-formation step when a specific impurity profile or crystal form is required for regulatory acceptance.
API concentration risk: what usually drives bottlenecks?
- Impurity profile alignment to specific specs used by a reference product and its ANDA bridging strategy
- Salt-form equivalence and particle/crystal attributes used in finished dose manufacturing
- Capacity planning around CNS launches and generic product cycles
- Raw material availability (key upstream intermediates feeding bupropion base)
Drug product concentration risk: what differs for extended-release?
Extended-release (XL-style) bupropion products add risk points:
- Controlled-release excipient sourcing
- Granulation and coating equipment utilization
- Batch-to-batch dissolution equivalence
- Scaling and hold-time controls affecting impurities
Which suppliers are best for long-term API continuity for bupropion (CNS brands and generics)?
Core answer: best continuity suppliers are those with (1) multiple DMF registrations, (2) demonstrated batch history for bupropion API with consistent impurity control, and (3) the ability to support salt formation and tech transfer under change control.
Supplier qualification checkpoints that affect onboarding timelines
- DMF completeness (API type, manufacturing steps, controls)
- Historical inspection record for the API site
- Capability for salt-form control (hydrobromide conversion or direct salt manufacture)
- Analytical package alignment (impurity panel, residual solvents, water content, polymorph/crystal attributes if specified)
What patents and regulatory filings affect bupropion supplier selection?
Core answer: for supplier sourcing, the most practical impact is not bupropion’s original drug patents. It is the regulatory and manufacturing acceptance pathway for generics and lifecycle changes, including NDA/ANDA site equivalence requirements.
What Orange Book and exclusivity status changes impact supplier risk?
For many bupropion products, exclusivity and patent barriers for initial generic entry have largely passed for older formulations. What still drives risk are:
- Lifecycle patents on specific formulations, release mechanisms, and manufacturing methods
- Citizen petitions and labeling disputes that can shift acceptable manufacturing specs
- Post-approval changes that trigger comparability requirements and could stall a supplier migration
What FDA regulatory pathways affect supplier onboarding?
- ANDA for generic bupropion products uses reference product comparisons and specs to demonstrate bioequivalence
- 505(b)(2) routes for formulation changes can impose additional bridging requirements
- DMF-linked manufacturing site changes can require supplements or prior approval depending on the change class
Which supplier routes are fastest: API-only, intermediate tolling, or finished-dose CMO?
Core answer: fastest route is typically direct API supply from a qualified DMF holder with active manufacturing history for bupropion, followed by salt formation capacity. Finished-dose CMOs accelerate time-to-market for launches but require formulation-specific qualification.
API-only route (highest speed if DMF is already mapped to your ANDA)
- Best when the supplier has established impurity specs and can support tech transfer quickly.
- Key is ensuring your ANDA strategy can reference or bridge to their API.
Intermediate tolling route (lower supply cost, higher integration time)
- Works when your team can manage intermediate-to-API process development under a controlled tech transfer.
- Higher chance of schedule slips due to impurity and salt conversion validation.
Finished-dose CMO route (fastest GTN, highest formulation/scale dependence)
- Most useful for extended-release where process sensitivity is high.
- Requires formulation and dissolution equivalence work to your target product profile.
What generic entry risks exist for bupropion that could force supplier changes?
Core answer: supplier changes can be forced by regulatory inspection outcomes, DMF updates, capacity constraints, or impurity excursions that impact batch release.
Typical failure points in bupropion supply substitutions
- Dissolution or dissolution-environment mismatch in extended-release products after excipient or process changes
- API impurity drift due to raw material changes
- Salt-form conversion variability (if hydrobromide conversion is part of your supply chain)
- Incomplete comparability packages for manufacturing changes
Supplier and litigation landscape: what should buyers screen for?
Core answer: buyers should screen supplier litigation history indirectly via FDA enforcement actions, warning letters, and inspection outcomes. For bupropion, litigation is usually tied to formulation/ANDA disputes rather than API production itself.
What to screen
- FDA inspection outcomes for API and finished dose sites
- DMF and site history for changes that triggered FDA follow-ups
- Recall history tied to product quality failures
- Any public import alerts impacting manufacturing sites
Key takeaways
- Bupropion hydrobromide supply is diversified across multiple API and drug product manufacturing sources; risk is usually localized to salt-formation control and impurity/spec alignment.
- Supplier selection should be built from DMF-linked API sources plus drug product manufacturing site verification from labeling and submissions, not from sales catalogs.
- For extended-release bupropion products, supplier onboarding depends more on dissolution and manufacturing process control than on API availability alone.
- Ongoing supplier qualification should focus on inspection outcomes, analytical control packages, and change-control readiness for impurity excursions and salt-form or excipient substitutions.
FAQs
1) Are bupropion hydrochloride and bupropion hydrobromide interchangeable for supply sourcing?
No. They are different salts and require equivalence decisions tied to finished-dose manufacturing specs, impurity profiles, and regulatory strategy.
2) What documents show the true API source for bupropion products?
API DMFs, ANDA manufacturing information, and label “manufactured for” statements tied to specific manufacturing sites.
3) Can a supplier change bupropion API suppliers without FDA action?
Not typically. Changes in API manufacturing site or process usually require comparability assessments and regulatory supplements depending on change class.
4) What’s the main supply risk for bupropion extended-release tablets?
Process sensitivity around controlled release and batch-to-batch dissolution performance, often influenced by API quality and excipient/process parameters.
5) How do buyers reduce risk when switching bupropion API suppliers?
Use a tech transfer plan with full analytical alignment to your target specs, include salt-form and impurity controls, and run stability and dissolution bridging where needed.
References
- U.S. Food and Drug Administration. Drug Master File (DMF) program and DMF-related guidance. FDA.
- U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA) regulations and guidance documents. FDA.
- U.S. Food and Drug Administration. Drug product manufacturing changes and comparability recommendations. FDA.
